Literature DB >> 9223560

The biodisposition and metabolism of anandamide in mice.

K A Willoughby1, S F Moore, B R Martin, E F Ellis.   

Abstract

The endogenous cannabinoid anandamide (AN) has been reported to produce pharmacological effects similar to those of delta9-tetrahydrocannabinol but with a shorter duration of action. Also, AN is known to be metabolized to arachidonic acid. The purpose of this study was to examine the time course of distribution and metabolism of AN. Male mice were each administered 20 microCi 3H-AN and 50 mg/kg AN (i.v.). At 1, 5, 15 and 30 min after administration, the animals were sacrificed, and various tissues were removed, solubilized and counted to determine the distribution of 3H. Also, samples from brain, adrenal gland and plasma were extracted with ethyl acetate and analyzed by HPLC to separate 3H-labeled AN, arachidonic acid and other metabolites. AN was detectable in brain by 1 min after injection. At 1 min after injection, the rank order of radioactivity per milligram or microliter of tissue was adrenal > lung > kidney > plasma > heart > liver > diaphragm > brain > fat. Although the 1 and 5 min metabolic profiles of brain 3H showed that AN was clearly present, most AN had already been transformed to arachidonic acid and other polar metabolites, and there were almost no detectable brain levels of AN at 15 and 30 min. In plasma and adrenal gland, AN was the predominant form at 1 and 5 min. Our experiments confirm that AN quickly reaches the brain and suggest that rapid metabolism of AN plays a key role in the time course of the pharmacological activity of this naturally occurring cannabinoid receptor ligand.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9223560

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  33 in total

1.  Evaluation of fatty acid amides in the carrageenan-induced paw edema model.

Authors:  Laura E Wise; Roberta Cannavacciulo; Benjamin F Cravatt; Billy F Martin; Aron H Lichtman
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

2.  Endocannabinoids inhibit the growth of free-living amoebae.

Authors:  Rafik Dey; Pierre Pernin; Jacques Bodennec
Journal:  Antimicrob Agents Chemother       Date:  2010-05-17       Impact factor: 5.191

Review 3.  Enzymatic pathways that regulate endocannabinoid signaling in the nervous system.

Authors:  Kay Ahn; Michele K McKinney; Benjamin F Cravatt
Journal:  Chem Rev       Date:  2008-04-23       Impact factor: 60.622

4.  Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase.

Authors:  B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

5.  The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys.

Authors:  Jennifer L Stewart; Lance R McMahon
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

6.  FAAH-/- mice display differential tolerance, dependence, and cannabinoid receptor adaptation after delta 9-tetrahydrocannabinol and anandamide administration.

Authors:  Katherine W Falenski; Andrew J Thorpe; Joel E Schlosburg; Benjamin F Cravatt; Rehab A Abdullah; Tricia H Smith; Dana E Selley; Aron H Lichtman; Laura J Sim-Selley
Journal:  Neuropsychopharmacology       Date:  2010-03-31       Impact factor: 7.853

7.  Cannabinoid CB1 Discrimination: Effects of Endocannabinoids and Catabolic Enzyme Inhibitors.

Authors:  Michael Z Leonard; Shakiru O Alapafuja; Lipin Ji; Vidyanand G Shukla; Yingpeng Liu; Spyros P Nikas; Alexandros Makriyannis; Jack Bergman; Brian D Kangas
Journal:  J Pharmacol Exp Ther       Date:  2017-09-25       Impact factor: 4.030

8.  Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.

Authors:  Leon Chang; Lin Luo; James A Palmer; Steven Sutton; Sandy J Wilson; Ann J Barbier; James Guy Breitenbucher; Sandra R Chaplan; Michael Webb
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

Review 9.  Cardiovascular effects of marijuana and synthetic cannabinoids: the good, the bad, and the ugly.

Authors:  Pal Pacher; Sabine Steffens; György Haskó; Thomas H Schindler; George Kunos
Journal:  Nat Rev Cardiol       Date:  2017-09-14       Impact factor: 32.419

Review 10.  Cannabinoid receptors and the regulation of bone mass.

Authors:  I Bab; A Zimmer
Journal:  Br J Pharmacol       Date:  2007-12-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.